4月24日晚间，奥精医疗科技股份有限公司（以下简称"奥精医疗"或"公司"）发布2024年业绩快报暨业 绩预告更正公告。修正后，公司2024年1-12月实现营业收入2.06亿元，同比下降9.03%，归属于母公司 股东的净利润-1266.22万元，同比下降123.35%；归属于母公司所有者的扣除非经常性损益的净利 润-2837.11万元，同比下降210.11%。 公告称，公司于2025年1月25日和2025年2月28日披露了公司2024年年度业绩预告和2024年度业绩快报， 现对相关内容修正。财务数据未经会计师事务所审计，具体以公司披露的2024年年度报告为准。 公司本次修正后的业绩快报暨业绩预告与公司已披露的《2024年年度业绩预告》和《2024年度业绩快 报》中主要财务数据的差异: (1)更正后的营业总收入为20,603.30万元，比修正前增加27.79万元，增幅0.14%； (2)更正后的营业利润为-736.09万元，比修正前增加701.35万元，增幅为48.79%； (3)更正后的利润总额为-89.64万元，比修正前增加710.34万元，增幅为44.29%； (4)更正后的归属于母公司所有者的净利润为-1 ...

Core Viewpoint - Keda Guokuan (科大国创) has significantly revised its 2024 performance forecast downward, now expecting a net loss of 5 to 10 million yuan, compared to the previous profit estimate of 22 to 33 million yuan [1][2] Group 1: Performance Revision - The company initially projected a net profit of 22 to 33 million yuan for 2024, reversing from a loss of 380 million yuan in the previous year [1] - The revised forecast indicates a net loss of 5 to 10 million yuan and a non-recurring loss of 42 to 47 million yuan [1][2] - The revision is attributed to overdue accounts receivable from certain clients and unexpected litigation, leading to a reassessment of the recoverability of these receivables [1][2] Group 2: Business Operations and Legal Issues - The issues stem from the company's digital logistics supply chain business, where overdue accounts and litigation have arisen [2] - As of April 7, the company reported a total of 230 million yuan in litigation and arbitration cases, accounting for 12.26% of its latest audited net assets [2] - The company has been actively pursuing legal action to recover overdue payments, with a total of 9630.13 million yuan in impairment provisions for accounts receivable recorded in the first three quarters of 2024 [3]